α2 激动剂治疗肠易激综合征的双盲研究。
Double-blind study of an alpha 2 agonist in the treatment of irritable bowel syndrome.
作者信息
Prior A, Wilson K M, Whorwell P J
机构信息
Department of Medicine, University Hospital of South Manchester, UK.
出版信息
Aliment Pharmacol Ther. 1988 Dec;2(6):535-9. doi: 10.1111/j.1365-2036.1988.tb00728.x.
A double-blind crossover trial of the alpha 2 agonist lidamidine hydrochloride in 72 patients with irritable bowel syndrome is reported. Lidamidine was found to have no significant effect on frequency and severity of abdominal pain or abdominal bloating. It did cause a statistically significant reduction in frequency of defaecation (P = 0.005), but this was of a degree unlikely to be of clinical importance. Although alpha 2 agonists inhibit gastrointestinal motility in animals this study suggests that lidamidine hydrochloride does not have a useful therapeutic role in irritable bowel syndrome.
本文报道了一项针对72例肠易激综合征患者的α2激动剂盐酸利达脒双盲交叉试验。结果发现，盐酸利达脒对腹痛频率和严重程度或腹胀并无显著影响。它确实使排便频率出现了具有统计学意义的降低（P = 0.005），但降低程度不太可能具有临床重要性。尽管α2激动剂在动物中可抑制胃肠蠕动，但本研究表明，盐酸利达脒在肠易激综合征中并无有效的治疗作用。
Zotero 插件